HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NAMS

NewAmsterdam Pharma Company NV

Last Close
Dec 12 • 02:27PM ET
25.08
Dollar change
-0.49
Percentage change
-1.90 		%
Healthcare • Biotechnology • Netherlands • NASD
Peers: JNJ PFE MRK BMY LLY GILD AMGN REGN VRTX BIIB
 | Held by: SBIO ONEQ GWX FHLC SMMV BBC FPXE
Scroll to Statements
Index- P/E- EPS (ttm)- Insider Own52.17% Shs Outstand92.17M Perf Week38.82%
Market Cap2.32B Forward P/E- EPS next Y-1.84 Insider Trans-0.18% Shs Float44.18M Perf Month1.31%
Income- PEG- EPS next Q-0.52 Inst Own40.63% Short Float5.86% Perf Quarter57.17%
Sales- P/S- EPS this Y4.34% Inst Trans0.24% Short Ratio4.24 Perf Half Y29.04%
Book/sh4.11 P/B6.10 EPS next Y10.32% ROA- Short Interest2.59M Perf Year154.41%
Cash/sh4.58 P/C5.48 EPS next 5Y- ROE- 52W Range9.61 - 27.29 Perf YTD124.57%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-8.08% Beta0.06
Dividend TTM- Quick Ratio10.61 Sales past 5Y-28.76% Gross Margin- 52W Low161.03% ATR (14)1.80
Dividend Ex-Date- Current Ratio10.61 EPS Y/Y TTM-210.57% Oper. Margin- RSI (14)64.63 Volatility9.22% 6.74%
Employees29 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price42.88
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-165.81% Payout- Rel Volume3.55 Prev Close25.57
Sales Surprise1455.07% EPS Surprise63.94% Sales Q/Q- EarningsNov 06 BMO Avg Volume610.68K Price25.08
SMA2016.47% SMA5023.36% SMA20028.92% Trades Volume1,674,652 Change-1.90%
Date Action Analyst Rating Change Price Target Change
May-15-24Initiated TD Cowen Buy
Mar-14-24Initiated Scotiabank Sector Outperform $35
Jan-18-24Initiated Guggenheim Buy $30
Jan-16-24Initiated Piper Sandler Overweight $37
Oct-30-23Initiated RBC Capital Mkts Outperform $25
Dec-11-24 09:37PM
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
(GlobeNewswire)
03:06PM
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
(Investor's Business Daily)
Dec-10-24 05:10PM
NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug
(Investor's Business Daily) +41.41%
04:34PM
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
(GlobeNewswire)
07:00AM
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
(GlobeNewswire)
04:01PM Loading…
Dec-06-24 04:01PM
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Nov-21-24 07:37AM
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results
(TipRanks)
Nov-20-24 04:13PM
NewAmsterdam Dives And Sacrifices A Cup Base Despite A Winning Cholesterol Study
(Investor's Business Daily) -15.50%
07:00AM
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
(GlobeNewswire)
Nov-18-24 03:20PM
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
(GlobeNewswire)
Nov-06-24 08:00AM
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
(GlobeNewswire) +13.73%
Nov-01-24 05:26PM
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Oct-28-24 04:30PM
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
(GlobeNewswire)
Oct-04-24 04:30PM
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Sep-06-24 04:32PM
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
08:00AM Loading…
Aug-30-24 08:00AM
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
(GlobeNewswire)
Aug-07-24 08:00AM
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
(GlobeNewswire)
Aug-02-24 04:01PM
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -6.35%
Jul-29-24 08:54AM
NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations
(Investor's Business Daily) -8.54%
08:00AM
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
(GlobeNewswire)
Jul-26-24 04:01PM
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
(GlobeNewswire)
Jul-18-24 08:00AM
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
(GlobeNewswire)
Jul-08-24 08:00AM
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
(GlobeNewswire)
Jul-03-24 04:01PM
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-11-24 08:00AM
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
(GlobeNewswire)
Jun-07-24 04:01PM
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
May-29-24 08:00AM
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
(GlobeNewswire)
May-21-24 08:00AM
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
(GlobeNewswire)
May-09-24 08:00AM
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
(GlobeNewswire)
May-03-24 04:01PM
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
08:00AM Loading…
May-02-24 08:00AM
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
(GlobeNewswire)
Apr-09-24 08:00AM
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
(GlobeNewswire)
Apr-01-24 08:00AM
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
(GlobeNewswire) -9.64%
Mar-25-24 08:00AM
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
(GlobeNewswire)
Mar-13-24 01:32PM
NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up
(Zacks)
Mar-12-24 08:00AM
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
(GlobeNewswire) +11.89%
Feb-28-24 08:33AM
NewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical Progress
(GuruFocus.com)
08:00AM
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
(GlobeNewswire)
Feb-26-24 08:00AM
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
(GlobeNewswire)
Feb-13-24 10:40PM
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
(GlobeNewswire)
04:01PM
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
(GlobeNewswire)
Feb-01-24 04:01PM
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
(GlobeNewswire) -6.01%
Jan-08-24 08:00AM
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
(GlobeNewswire)
Jan-04-24 08:00AM
NewAmsterdam Pharma Announces 2024 Strategic Priorities
(GlobeNewswire)
Nov-13-23 09:55AM
Forbion co-leads 129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023
(GlobeNewswire) -6.91%
08:00AM
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
(GlobeNewswire)
Oct-31-23 12:05PM
RBC initiates coverage of NewAmsterdam on CETP inhibitor
(Yahoo Finance Video) +25.52%
Oct-30-23 09:43AM
AbbVie upgraded, Cisco downgraded: Wall Street's top analyst calls
(The Fly) +7.01%
Oct-23-23 08:00AM
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
(GlobeNewswire) -10.07%
Oct-17-23 03:00AM
Tessellate BIO Emerges from Stealth
(GlobeNewswire)
Sep-21-23 07:00AM
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimers Disease Who Carry an ApoE4 Mutation
(GlobeNewswire)
Sep-20-23 08:00AM
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
(GlobeNewswire)
Aug-14-23 04:01PM
NewAmsterdam Pharma Announces Appointment of William BJ Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
(GlobeNewswire)
Aug-10-23 06:01AM
NewAmsterdam Pharma First Half 2023 Earnings: 0.92 loss per share (vs 1.50 profit in 1H 2022)
(Simply Wall St.)
Aug-07-23 07:15AM
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
(GlobeNewswire)
Jul-25-23 04:01PM
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease
(GlobeNewswire)
Jun-09-23 04:01PM
NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
(GlobeNewswire)
Jun-06-23 11:25PM
NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares
(GlobeNewswire) -16.52%
04:01PM
NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares
(GlobeNewswire)
Jun-05-23 07:00AM
NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
(GlobeNewswire)
Jun-03-23 12:15PM
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
(GlobeNewswire)
May-31-23 08:00AM
NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
(GlobeNewswire)
May-23-23 08:00AM
NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
(GlobeNewswire)
May-08-23 08:00AM
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights
(GlobeNewswire)
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ForGrowth NAP B.V.10% OwnerNov 18 '24Sale25.0833,273834,44011,778,760Nov 19 04:15 PM
ForGrowth NAP B.V.10% OwnerNov 15 '24Sale25.028,530213,43611,812,033Nov 19 04:15 PM
ForGrowth NAP B.V.10% OwnerNov 14 '24Sale25.019,832245,85611,820,563Nov 15 04:36 PM
ForGrowth NAP B.V.10% OwnerNov 13 '24Sale25.001,06626,65511,830,395Nov 15 04:36 PM
NAP PoolCo B.V.AffiliateNov 13 '24Proposed Sale24.981,553,75938,812,900Nov 13 04:23 PM
Kooij Louise FrederikaChief Accounting OfficerOct 01 '24Sale15.7245,000707,4000Oct 01 05:23 PM
Kooij Louise FrederikaOfficerOct 01 '24Proposed Sale17.2945,000778,050Oct 01 05:12 PM
Audet Juliette BerangereChief Business OfficerSep 26 '24Buy15.701,10417,3331,104Sep 30 05:22 PM
Davidson Michael H.Chief Executive OfficerAug 20 '24Buy16.275,00081,350209,784Aug 22 04:30 PM
Davidson Michael H.Chief Executive OfficerJun 20 '24Buy17.265,00086,308204,784Jun 24 08:30 AM
Topper James NDirectorMar 26 '24Buy21.508,429181,2243,008,429Mar 28 04:30 PM
Kastelein Johannes Jacob PieteChief Scientific OfficerMar 26 '24Sale21.50190,4764,095,2340Mar 27 04:30 PM
LANGE LOUIS GDirectorFeb 13 '24Buy19.005,00095,00024,878Feb 21 05:00 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.